Camrelizumab or envafolimab
Phase 2Monoclonal antibody
Camrelizumab or envafolimab is one of 38 small molecule programs targeting Cholangiocarcinoma. It is currently in Phase 2.
1
Indications
4
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
45 competitors in Cholangiocarcinoma
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Zykadia
NovartisApproved
Rocaltrol
Jazz PharmaceuticalsApproved
Camptosar
PfizerApproved
Colcrys
Jazz PharmaceuticalsApproved
Ixempra
RR-Pharm
Approved
Wellcovorin
GGlaxo Dba Glaxosmithkline
Approved
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Tecentriq
RochePhase 3
Alinamin
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Gastric Cancer2 trials
Leptomeningeal Metastasis1 trial
Cholangiocarcinoma1 trial
Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
Enrolling by invitation·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT06901622·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Camrelizumab or envafolimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 2[1]
- Company
- HHebei Medical University